Team

BioTeam is primarily a group of scientists who were forced to learn I.T., software development and High Performance Computing to get their research done. We all found great satisfaction in understanding and leveraging these technologies to drive our own research and that of our colleagues. This passion for ‘Bio-IT’ is a natural fit for BioTeam which has been focused on using I.T. to enable science since the company’s inception in 2002.

 
Victor Tetz

Victor Tetz, MD, Ph.D
Dr. Tetz serves as Scientific Advisor and is responsible for the strategic planning for TGV-inhalonix. Prior to founding TGV-inhalonix, Victor successfully worked in senior positions in drug development companies.

  • Over 25 years of experience in drug discovery.
  • Senior Investigator and Group Leader in Microbiology Research for the company conducting research for Pepsi, Gen3Partners, Dole and others
  • Member of the American Society for Microbiology.

George Tetz

George Tetz, MD, Ph.D

Dr. George Tetz serves as a CEO and Senior Director Clinical Development. During his career, Dr. G.Tetz has held executive positions with several biotech companies.

  • Dr. G. Tetz has been in the background of numerous groundbreaking studies in the fields of microbiology and virology aimed at discovering novel regulation pathways in microbial communities, particularly within the human microbiota; discovering novel bacterial species, including several whose role in cancer is now under review; the development of novel theoretical concepts that have led to the reevaluation of the accepted causes of many diseases; the discovery of new human pathologies.
  • Author of over 15 patents in the field of microbiology
  • Active member of family pharmaceutical business founded in the mid-19th century
  • Prior to joining TGV, George has worked in numerous collaborative drug discovery programs, and contributed to more than 18 novel candidates moving into clinical development.In five years Dr. G. Tetz brought a drug candidate for the treatment of acute liver injury from the animal proof-of-efficacy stage to the successful completion of Phase III trial (outside the US).
  • In total, Dr. G. Tetz has over 16 years of experience in microbiological research and drug discovery. He is currently a member of the American Chemical Society and the American Society for Microbiology.

Jeffrey A. Gelfand

Jeffrey A. Gelfand, MD, Ph.D

Dr. Jeffrey A. Gelfand, serves as a Chairman of the Scientific Advisory Board. Dr. Jeffrey A. Gelfand is a Professor and Chairman of the Department of Medicine at Tufts and Physician-in-Chief at the New England Medical center. He is currently an attending physician at Massachusetts General Hospital, a Clinical Professor at Harvard Medical School, and Professor of Medicine at Tufts. Dr. Gelfand conducts laboratory and clinical research in immunology, inflammation, infection, and tumor immunology.

  • 20 years of investment pharmaceutical R&D
  • Prior to joining TGV, Jeffrey was a Chief Scientific Officer & Founder Boston BioCom LLC, President of Pratt Medical Group
  • Over the last years, he has been increasingly active in the drug discovery and development
  • Manages the research at the M.G.H. (Massachusetts General Hospital) Research Center with an annual budget of over $600 mln
  • Jeffrey is a Clinical Professor, Department of Medicine, Harvard Medical School, member of AAAS

Sushant Kumar

Sushant Kumar, MD, Ph.D

Dr Sushant is responsible for the management of all operational aspects and investment.

  • Responsible for the management strategy and analysis
  • Over 12 years experience in healthcare research and investment management.

Michael Cynamon

Michael Cynamon, MD, Ph.D

Dr, Cynamon serves as a Member of Scientific Advisory Board. Dr. Michael Cynamon is an infectious disease specialist in Syracuse, New York and is affiliated with Syracuse Veterans Affairs Medical Center. He received his medical degree from Yale University School of Medicine and has been in practice for 43 years.He is a leading researcher in pulmonary infections with more than 35 years experience in healthcare research.

Haran Schlamm, MD

Dr. Haran Schlamm, is a globally recognized infectious disease-trained physician. He has 20+ years pharmaceutical industry experience in clinical development and medical affairs seeking opportunities to support the development of novel anti-infective agents. Dr. Schlamm was the clinical lead for antifungals drugs to treat lung infections at Pfizer for 20+ years

Michelle Welborn

Dr. Michelle Welborn

Dr. Michelle Welborn, serves as a pharmaceutical consultant and provides regulatory consulting to manage the project in FDA. Michelle Welborn holds a Doctor of Pharmacy degree from Campbell University School of Pharmacy. Michelle has 15 years experience in pharmaceuticals as a liaison in Medical and Regulatory Affairs for both Astra-Merck and Sanofi –Aventis Pharmaceuticals, and as Clinical Pharmacy Manager for a Health Maintenance Organization (HMO) , and as a Pharmacy Practice resident at Wake Forest University Baptist Medical CenterShe has participated in workshops and consortiums organized by the NIH (National Institutes of Health), the National Organization of Rare Diseases (NORD), the International Congress of Rare Diseases (ICORD), and the Centers for Disease Control (CDC), the Epilepsy Foundation of America, and the Australian Dravet syndrome Family Day. She served for two years as the Professional Advisory Board Chair for the IDEA League before founding ICE. She currently serves on the Professional Advisory Boards for the Charlie Foundation and Lennox-Gastaut Syndrome Foundation.